A Phase II Study of NirAparib, Dostarlimab and Radiotherapy in Metastatic, PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR) TBCRC-055 20-649
Clinical Trial Grant
Awarded By
GlaxoSmithKline
Start Date
September 5, 2024
End Date
March 31, 2028
Awarded By
GlaxoSmithKline
Start Date
September 5, 2024
End Date
March 31, 2028